this was bound to happen with the number of compounding pharmacies getting into the glp-1 game. from a risk side, it’s a total mess it’s basically impossible for insurers to model long-term liability when the supply chain for these drugs is a black box. fda had to drop the hammer before the claims started flying.
I think this will act as a brake on the agentic shift as a whole.
if a company sells an autonomous agent that is marketed as doing a task without human oversight, the courts will eventually move that burden back to the manufacturer. we saw the same dance with autonomous driving disclaimers the "human must stay in control" line works as a legal shield for a while, but eventually the market demands a shift in who holds the risk.
if we stick to 100% human responsibility for black-box errors that a human couldn't have even predicted, that "brake" won't just slow down the agentic shift, it'll effectively kill the enterprise market for it. no C-suite is going to authorize a fleet of agents if they're holding 100% of the bag for emergent failures they can't audit.